Table 4.
Visual field grade change at 3 months, 6 months, 9 months, 15 months, and 2 to 5 years from initial visit, in those seen within 3 months of onset.
| Follow-up/Initial Visual Field | Non-ischemic CRVO (n=365**) |
Ischemic CRVO (as first diagnosis) (n=66**) |
Ischemic CRVO (converted from non-ischemic) (n=41**) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| n** | Number (%) of eyes |
n** | Number (%) of eyes |
n** | Number (%) of eyes |
||||
| Improved | Worsened | Improved | Worsened | Improved | Worsened | ||||
| 3 months* | (n=306) | (n=60) | (n=36) | ||||||
| Minimal | 199 | 17 (9%) | 36 (18%) | 0 | -- | -- | 0 | -- | -- |
| Mild | 80 | 38 (48%) | 12 (15%) | 5 | 0 (0%) | 3 (60%) | 10 | 0 (0%) | 6 (60%) |
| Moderate | 25 | 10 (40%) | 6 (24%) | 31 | 4 (13%) | 14 (45%) | 17 | 3 (18%) | 8 (47%) |
| Marked | 2 | 1 (50%) | 0 | 22 | 4 (18%) | 7 (32%) | 8 | 1 (12%) | 2 (25%) |
| Severe | 0 | -- | -- | 2 | 0 | 0 | 1 | 0 | 0 |
| Minimal to mild | 279 | 55 (20%) | 48 (17%) | 5 | 0 (0%) | 3 (60%) | 10 | 0 (0%) | 6 (60%) |
| Moderate to severe | 27 | 11 (41%) | 6 (22%) | 55 | 8 (15%) | 21 (38%) | 26 | 4 (15%) | 10 (38%) |
| 6 months* | (n=249) | (n=54) | (n=33) | ||||||
| Minimal | 162 | 23 (14%) | 35 (22%) | 0 | -- | -- | 0 | -- | -- |
| Mild | 66 | 35 (53%) | 12 (18%) | 4 | 0 (0%) | 3 (75%) | 9 | 0 (0%) | 7 (78%) |
| Moderate | 20 | 8 (40%) | 4 (20%) | 30 | 6 (20%) | 15 (50%) | 13 | 2 (15%) | 10 (77%) |
| Marked | 1 | 1 (100%) | 0 | 19 | 4 (21%) | 8 (42%) | 10 | 2 (20%) | 2 (20%) |
| Severe | 0 | -- | -- | 1 | 0 | 0 | 1 | 1 (100%) | 0 |
| Minimal to mild | 228 | 58 (25%) | 47 (21%) | 4 | 0 (0%) | 3 (75%) | 9 | 0 (0%) | 7 (78%) |
| Moderate to severe | 21 | 9 (43%) | 4 (19%) | 50 | 10 (20%) | 23 (46%) | 24 | 5 (21%) | 12 (50%) |
| 9 months* | (n=220) | (n=50) | (n=34) | ||||||
| Minimal | 144 | 15 (10%) | 29 (20%) | 0 | -- | -- | 0 | -- | -- |
| Mild | 53 | 34 (64%) | 10 (19%) | 6 | 0 (0%) | 4 (67%) | 8 | 0 (0%) | 6 (75%) |
| Moderate | 22 | 13 (59%) | 4 (18%) | 28 | 5 (18%) | 16 (57%) | 17 | 3 (18%) | 13 (76%) |
| Marked | 1 | 0 | 0 | 14 | 2 (14%) | 6 (43%) | 8 | 2 (25%) | 1 (12%) |
| Severe | 0 | -- | -- | 2 | 0 | 0 | 1 | 1 (100%) | 0 |
| Minimal to mild | 197 | 49 (25%) | 39 (20%) | 6 | 0 (0%) | 4 (67%) | 8 | 0 (0%) | 6 (75%) |
| Moderate to severe | 23 | 13 (57%) | 4 (17%) | 44 | 7 (16%) | 22 (50%) | 26 | 6 (23%) | 14 (54%) |
| 15 months* | (n=185) | (n=42) | (n=30) | ||||||
| Minimal | 116 | 15 (13%) | 22 (19%) | 0 | -- | -- | 0 | -- | -- |
| Mild | 51 | 34 (67%) | 8 (16%) | 5 | 0 (0%) | 4 (80%) | 7 | 0 (0%) | 7 (100%) |
| Moderate | 17 | 11 (65%) | 4 (24%) | 23 | 6 (26%) | 13 (57%) | 15 | 2 (13%) | 12 (80%) |
| Marked | 1 | 1 (100%) | 0 | 13 | 3 (23%) | 7 (54%) | 8 | 2 (25%) | 3 (38%) |
| Severe | 0 | -- | -- | 1 | 0 | 0 | 1 | 1 (100%) | 0 |
| Minimal to mild | 167 | 49 (29%) | 30 (18%) | 5 | 0 (0%) | 4 (80%) | 7 | 0 (0%) | 7 (100%) |
| Moderate to severe | 18 | 12 (67%) | 4 (22%) | 37 | 9 (24%) | 20 (54%) | 24 | 5 (21%) | 15 (62%) |
| 2 to 5 years* | (n=199) | (n=37) | (n=30) | ||||||
| Minimal | 134 | 26 (19%) | 22 (16%) | 0 | -- | -- | 0 | -- | -- |
| Mild | 46 | 37 (80%) | 5 (11%) | 4 | 0 (0%) | 3 (75%) | 7 | 0 (0%) | 7 (100%) |
| Moderate | 19 | 15 (79%) | 3 (16%) | 21 | 5 (24%) | 12 (57%) | 14 | 3 (21%) | 10 (71%) |
| Marked | 0 | -- | -- | 12 | 4 (33%) | 7 (58%) | 9 | 1 (11%) | 5 (56%) |
| Severe | 0 | -- | -- | 0 | -- | -- | 0 | -- | -- |
| Minimal to mild | 180 | 63 (35%) | 27 (15%) | 4 | 0 (0%) | 3 (75%) | 7 | 0 (0%) | 7 (100%) |
| Moderate to severe | 19 | 15 (79%) | 3 (16%) | 33 | 9 (27%) | 19 (58%) | 23 | 4 (17%) | 15 (65%) |
*
± 6 weeks for 3, 6, and 9 months; ±12 weeks for 15 months
**
Total number of eyes that had at least one follow-up period in which visual field change was assessed
CRVO = Central retinal vein occlusion